Business Description
Zevra Therapeutics is a Boston-based company focused on bringing effective treatments to patients living with rare and often overlooked medical conditions. The company markets several approved products, including AZSTARYS for ADHD, OLPRUVA for urea cycle disorders, and MIPLYFFA for a rare neurological condition, while also advancing multiple drug candidates through late-stage clinical trials. Zevra works with partners such as Commave Therapeutics and Relief Therapeutics to develop and commercialize its pipeline. Founded in 2006 and formerly known as KemPharm, the company rebranded under its current name in early 2023.
